Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL4778411 | 1.00 | MAPT (0.50) | MAPTLMNAALDH1A1OR51E2TDP1 | |
| Piperazine SCHEMBL6371041 | 0.96 | LMNA (0.46) | MAPTLMNAALDH1A1OR51E2TDP1 | |
| Piperazine SCHEMBL28250842 | 0.96 | MAPT (0.46) | MAPTLMNAALDH1A1OR51E2TDP1 | |
| Urea SCHEMBL1769303 | 0.96 | — | — | |
| Urea SCHEMBL2677624 | 0.89 | SMN1; SMN2 (0.60) | MAPTLMNAALDH1A1OR51E2TDP1 | |
| Piperazine SCHEMBL11443166 | 0.88 | MAPT (0.46) | MAPTLMNAALDH1A1OR51E2TDP1 | |
| Piperazine SCHEMBL30586091 | 0.88 | ACHE (0.54) | MAPTLMNAALDH1A1OR51E2TDP1 | |
| Piperazine SCHEMBL250578 | 0.88 | ACHE (0.54) | MAPTLMNAALDH1A1OR51E2TDP1 | |
| Urea SCHEMBL9063194 | 0.88 | ALDH1A1 (0.46) | MAPTLMNAALDH1A1OR51E2TDP1 | |
| Piperazine SCHEMBL6947881 | 0.87 | TSHR (0.42) | MAPTLMNAALDH1A1OR51E2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107417578-A | N (base of 3,5 dimethyladamantane 1) N ' substituted phenylurea compounds and its production and use | 沈阳海诺威医药科技有限公司 | 2017-12-01 | — | — | CN | claimed |
| CN-104130259-B | A kind of ring-closure reaction method of caffeine intermediate 1,3-dimethyl-4-amino-5-formamido group urea piperazine | SHIJIAZHUANG PHARMACEUTICAL GROUP NEW NORWICH PHARMACEUTICAL Co.,Ltd. (CN) | 2016-01-13 | — | — | CN | claimed |
| CN-103360393-B | The preparation method of theophylline acetic acid | SHANGHAI WANXIANG PHARMACEUTICAL CO., LTD. (CN) | 2016-01-06 | — | — | CN | claimed |
| CN-104130259-A | Ring-closure reaction method of caffeine intermediate 1,3-dimethyl-4-amino-5-formyl aminoureazine (FAU) | SHIJIAZHUANG PHARM GROUP OUYI | 2014-11-05 | — | — | CN | claimed |
| CN-103360393-A | Preparation method of theophylline-7-acetic acid | SHANGHAI WANXIANG PHARMACEUTICAL CO LTD | 2013-10-23 | — | — | CN | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | claimed |
| CN-100493705-C | Swollen vermiculite loading NiB amorphous alloy catalyst preparation method and application | UNIV NANKAI (CN) | 2009-06-03 | — | — | CN | claimed |
| CN-101257895-A | Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility | SCHERING AG (DE) | 2008-09-03 | — | — | CN | claimed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| CN-101015804-A | Swollen vermiculite loading NiB amorphous alloy catalyst, its prepn. method and application | UNIV NANKAI (CN) | 2007-08-15 | — | — | CN | claimed |
| EP-1608373-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040023979-A1 | Process for making substituted thiazolyl-amino pyridines | ZHAO MATTHEW M (US) | 2004-02-05 | — | — | US | claimed |
| CN-118325568-A | Method for increasing adhesive force of sandwich panel | 江苏逸欣节能科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2023230480-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT AND PREVENTION OF HIV | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-11-30 | — | — | WO | disclosed |
| CN-114702439-B | Naphthyl urea-piperazine compound and preparation method and application thereof | 河南省锐达医药科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20040023979-A1 | Process for making substituted thiazolyl-amino pyridines | ZHAO MATTHEW M (US) | 2004-02-05 | — | — | US | disclosed |
| US-20030087913-A1 | Solid pharmaceutical agent formulation for a piperazine urea derivative | SCHERING AG (DE) | 2003-05-08 | — | — | US | disclosed |
| US-20030087913-A1 | Solid pharmaceutical agent formulation for a piperazine urea derivative | SCHERING AG (DE) | 2003-05-08 | — | — | US | disclosed |
| WO-2003035037-A1 | SOLID PHARMACEUTICAL FORMULATION FOR A PIPERAZINE UREA DERIVATIVE | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087913-A1 | Solid pharmaceutical agent formulation for a piperazine urea derivative | SLC14A1, UTS2R, SP1 | MAPT 325/4885LMNA 4411/4885ALDH1A1 1795/4885 |
| US-20040023979-A1 | Process for making substituted thiazolyl-amino pyridines | ERBB2, ERBB4, TYRO3 | MAPT 3420/4885LMNA 4770/4885ALDH1A1 3570/4885 |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | MAPT 2716/4885LMNA 2968/4885ALDH1A1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.